{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=abraxane&page=14", "query": { "intervention": "abraxane", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 2451, "total_pages": 246, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=abraxane&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=abraxane&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T02:32:54.262Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03013218", "title": "A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Solid Tumor", "Advanced Cancer", "NonHodgkin Lymphoma" ], "interventions": [ { "name": "Evorpacept (ALX148)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Ramucirumab + Paclitaxel", "type": "DRUG" }, { "name": "5-FU + Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ALX Oncology Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 174, "start_date": "2017-02-03", "completion_date": "2025-07-08", "has_results": false, "last_update_posted_date": "2025-08-01", "last_synced_at": "2026-10-27T02:32:54.262Z", "location_count": 6, "location_summary": "Denver, Colorado • New Haven, Connecticut • Boston, Massachusetts + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03013218" }, { "nct_id": "NCT03642990", "title": "NR in Chemo-induced Peripheral Neuropathy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chemotherapy-induced Peripheral Neuropathy", "Breast Cancer Metastatic", "Platinum-resistant Recurrent Ovarian Cancer", "Head and Neck Cancer Stage IV", "Endometrial Cancer Stage IV" ], "interventions": [ { "name": "Nicotinamide Riboside", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Donna Hammond, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 5, "start_date": "2019-11-08", "completion_date": "2022-02-24", "has_results": true, "last_update_posted_date": "2023-04-12", "last_synced_at": "2026-10-27T02:32:54.262Z", "location_count": 2, "location_summary": "Iowa City, Iowa • Winston-Salem, North Carolina", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03642990" }, { "nct_id": "NCT00960960", "title": "A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Pictilisib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2009-08", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2016-12-15", "last_synced_at": "2026-10-27T02:32:54.262Z", "location_count": 3, "location_summary": "Peoria, Illinois • Boston, Massachusetts • Nashville, Tennessee", "locations": [ { "city": "Peoria", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00960960" }, { "nct_id": "NCT00278122", "title": "Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2005-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-10", "last_synced_at": "2026-10-27T02:32:54.262Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00278122" }, { "nct_id": "NCT00803062", "title": "Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Cervical Squamous Cell Carcinoma", "Recurrent Cervical Carcinoma", "Stage IVB Cervical Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Topotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 452, "start_date": "2009-04", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2019-07-23", "last_synced_at": "2026-10-27T02:32:54.262Z", "location_count": 541, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 351 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00803062" }, { "nct_id": "NCT00102622", "title": "Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Intraperitoneal tgDCC-E1A", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 18, "start_date": "2004-12-01", "completion_date": "2012-07", "has_results": false, "last_update_posted_date": "2018-11-13", "last_synced_at": "2026-10-27T02:32:54.262Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00102622" }, { "nct_id": "NCT03783442", "title": "A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Esophageal Squamous Cell Carcinoma (ESCC)" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Tislelizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 649, "start_date": "2018-12-11", "completion_date": "2024-08-22", "has_results": true, "last_update_posted_date": "2025-07-29", "last_synced_at": "2026-10-27T02:32:54.262Z", "location_count": 2, "location_summary": "New Haven, Connecticut • The Woodlands, Texas", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03783442" }, { "nct_id": "NCT03574779", "title": "A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Neoplasms" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "TSR-042", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 77, "start_date": "2018-11-15", "completion_date": "2025-03-31", "has_results": true, "last_update_posted_date": "2025-07-15", "last_synced_at": "2026-10-27T02:32:54.262Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Ventura", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03574779" }, { "nct_id": "NCT04016389", "title": "FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trachelectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University Health Network, Toronto", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "18 Years to 40 Years · Female only" }, "enrollment_count": 31, "start_date": "2020-02-11", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2025-08-12", "last_synced_at": "2026-10-27T02:32:54.262Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04016389" }, { "nct_id": "NCT01422889", "title": "ION US Post-Approval Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Atherosclerosis", "Coronary Artery Disease" ], "interventions": [ { "name": "ION™ Coronary Stent System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Boston Scientific Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "110 Years", "sex": "ALL", "summary": "18 Years to 110 Years" }, "enrollment_count": 1120, "start_date": "2011-09", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2016-02-04", "last_synced_at": "2026-10-27T02:32:54.262Z", "location_count": 40, "location_summary": "Jonesboro, Arkansas • Bakersfield, California • San Diego, California + 33 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01422889" } ] }